Your session is about to expire
← Back to Search
LUM-201 for Human Growth Hormone Deficiency (OraGrowtH213 Trial)
OraGrowtH213 Trial Summary
This trial is studying the growth response to a new drug, LUM-201, in children with GHD who have previously been treated with another growth hormone for 12 months.
OraGrowtH213 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.OraGrowtH213 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not on medication that could affect my growth or response to growth treatments.I am on long-term medication that affects how my body processes certain drugs.You must have already finished 12 months of daily rhGH treatment as part of the LUM-201-01 PGHD trial.
- Group 1: LUM-201 (3.2 mg/kg/day)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned LUM-201 for general use?
"LUM-201 has been evaluated for safety in a Phase 2 trial, so it was given an assessment of 2 on the 1 to 3 scale. No evidence exists verifying efficacy yet."
Are individuals aged sixty or younger eligible for this research initiative?
"The eligibility criteria for this clinical trial are candidates aged three to thirteen years old."
Are there any vacancies for volunteers in this trial?
"Information on clinicaltrials.gov states that this investigation is not presently recruiting patients for enrollment. The trial was first listed on February 18th 2022 and last edited in August of the same year, but 24 other studies are actively welcoming new participants at present."
Am I eligible to take part in this medical experiment?
"This investigation requires 20 participants aged between 3 and 13 with human growth hormone deficiency to sign an informed consent along with their caretaker (where applicable). Moreover, applicants must have completed the prior LUM-201-01 PGHD trial for 12 months daily rhGH treatment; eligibility will be established by the principal investigator."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger